组织蛋白酶D和nm23基因蛋白在乳腺癌中的表达及与淋巴结转移的关系

采用免疫组织化学 ABC法检测了 43例乳腺癌中的组织蛋白酶 D和 nm 2 3基因蛋白的表达。结果显示组织蛋白酶D在乳腺癌组织中表达阳性率为 76 .7% (33/43)。 43例乳腺癌中 2 5例伴有淋巴结转移 ,18例无淋巴结转移 ,其组织蛋白酶D表达阳性率分别为 92 % (2 3/2 5 )及 5 5 .6 % (10 /18) ,两者之间具有显著性差异 (P<0 .0 1)。 nm 2 3基因蛋白在 43例乳腺癌中阳性率为 72 .1% (31/43)。在有淋巴结转移和无淋巴结转移的乳腺癌中 nm2 3基因蛋白阳性率分别为 6 0 % (15 /2 5 )及80 .9% (16 /18) ,nm2 3基因蛋白的表达与淋巴结转移呈显著负相关 (P<0 .0 5 )。结果提示对乳腺癌根治术后无淋巴结转移 ,但组织蛋白酶 D表达阳性 ,nm2 3基因蛋白表达阴性的患者 ,可能具有潜在的复发和转移倾向 ,应多加关注 ,并密切随访。     

MMP-3与乳腺癌上皮间质转化的关系及其意义

为了探讨MMP-3在乳腺癌中表达与乳腺癌上皮间质转化的关系及其在乳腺癌浸润转移中的作用.采用免疫组织化学检测正常乳腺组织、乳腺癌癌旁组织、乳腺癌组织中MMP-3、Claudin-1、Vimentin的表达情况.研究发现:1)MMP-3在乳腺癌组织的阳性表达率较癌旁组织及正常乳腺组织高且具有统计学意义(P<0.05).Claudin-1在乳腺癌中的阳性表达率明显低于癌旁组织及正常乳腺组织具有统计学意义(P<0.05).Vimentin在乳腺癌组织阳性表达率高于癌旁组织及正常乳腺组织具有统计学意义(P<0.05);2)随着乳腺癌病理分期的增加MMP-3表达逐渐增加,同时出现Claudin-1蛋白表达降低及Vimentin蛋白表达升高.相关分析表明MMP-3与Claudin-1的表达呈负相关(r=-0.301,P=0.019),与Vimentin的表达呈正相关(r=0.378,P=0.03),Claudin-1与Vimentin的表达呈负相关(r=-0.278,P=0.031).结果提示,MMP-3可能是通过介导乳腺癌细胞发生上皮间质转化来参与乳腺癌的浸润转移.     

乳腺癌肺耐药蛋白表达及其与C-erbB-2和p53表达的关系

目的　探讨LRP在乳腺癌组织中的表达及其与C erbB 2和 p5 3表达的相关性。方法　采用免疫组化LSAB法检测 15 2例乳腺癌组织和 40例正常乳腺组织的LRP、C erbB 2和 p5 3蛋白的表达水平 ,并将结果与临床病理因素和预后资料进行分析。结果　在 15 2例乳腺癌组织中LRP、C erbB 2和 p5 3阳性例数分别为 12 2 ( 80 2 % )、 10 2 ( 67 1% )和 69( 45 4% ) ,乳腺对照组织LRP阳性 2 2例 ( 5 5 0 % ) ;乳腺癌组织LRP的表达明显高于对照组 ( χ2 =10 70 9,P <0 0 1) ,并与C erbB 2 ( χ2 =12 44 0 ,P <0 0 1,γ =0 2 9)和 p5 3 ( χ2 =8 5 0 0 ,P <0 0 1,γ =0 2 5 )表达呈正相关 ;在淋巴结转移组LRP阳性 62例 ( 88 6% ) ,无转移组阳性 60例 ( 73 2 % ) ,LRP的表达与淋巴结转移 ( χ2 =5 65 4,P <0 0 5 ,γ =0 19)呈正相关。单因素预后分析显示LRP阳性组生存期明显低于阴性组 ( χ2 =7 0 92 ,P <0 0 1)。结论　C erbB 2和p5 3可能诱导LRP表达上调 ,LRP表达可能与腋淋巴结转移、缩短常规化疗乳腺癌患者生存期有关     

抗转移癌基因在乳腺癌中的表达及其与淋巴结转移和预后的关系

观察 nm2 3 在乳腺癌中的表达与淋巴结转移和预后的关系。方法 :应用免疫组化 L SAB法检测 15 2例乳腺癌 nm2 3、ER、 PR、 P5 3和 PCNA的表达水平 ,比较 nm2 3 的表达对淋巴结转移和预后的影响。结果 :(1)在淋巴结转移组 nm2 3表达例数 32例 (4 5 .7% ) ,无转移组表达 40例 (4 8.8% ) ,两者差异无显著性 (P>0 .0 5 ) ;(2 )在 PCNA高指数表达组 nm2 3 阳性 42例 (6 0 .9% ) ,低指数表达组 nm2 3阳性 30例 (36 .1% ) ,前者明显高于后者 (χ2 =9.2 39,P<0 .0 1) ,且 PCNA与nm2 3 两因素呈正相关关系 (γs=0 .30 4,P<0 .0 1) ;(3)临床病理多因素比例风险回归分析显示淋巴结转移是影响患者生存的主要因素 ,而 nm2 3 对患者生存期无影响。结论 :nm2 3在乳腺癌中的表达既不能预测淋巴结转移 ,也不能提示较长的生存期 ,可能与肿瘤细胞的活跃增生有关。     

TDGF-1在胃癌中表达的意义及其在上皮间质转化中的作用

探讨胚胎瘤衍生生长因子(teratocarcinoma-derived growth factor-1,TDGF-1)在胃癌中表达的临床意义及其与上皮间质转化(epithelial-mesenchymal transition,EMT)的关系.分别采用免疫组化SP法和逆转录-聚合酶连反应(RT-PCR)方法,检测胃癌组织和正常胃组织中TDGF-1、E-cadherin、Vimentin的表达情况(IHC70例;RT-PCR40例),分析TDGF-1表达与临床病理特征的关系及TDGF-1、E-cadherin、Vimentin三者表达的相关性.TDGF-1、E-cadherin、Vimentin蛋白在胃癌组织中的阳性表达率分别为70%、34.3%、52.9%,在正常胃组织中的阳性表达率分别为38.5%、94.3%、15.7%(P<0.05);TDGF-1、E-cadherin、Vimentin mRNA在胃癌组织中的阳性表达率分别为67.5%、37.5%、52.5%,在正常胃组织中的阳性表达率分别为35%、87.5%、22.5%(P<0.05);TDGF-1蛋白和mRNA的表达均与胃癌的浸润深度、淋巴结转移及TNM分期显著相关(P<0.05);TDGF-1高表达与E-cadherin表达减低显著相关(r=-0.447、P<0.05),TDGF-1高表达与Vimentin表达升高显著相关(r=0.318、P<0.05),E-cadherin表达减低与Vimentin表达升高显著相关(r=-0.283、P<0.05).TDGF-1可能通过调控E-cadherin、Vi-mentin表达促进EMT,从而在胃癌的侵袭转移中发挥重要作用.     

血管紧张素Ⅱ受体1、VEGF和MVD在乳腺癌中的表达及相关性研究

目的:研究AT1受体、VEGF和CD34在乳腺癌中的表达、并探讨其相关性及临床意义。方法:该实验采用免疫组化方法(SP法),对102例乳腺癌患者石蜡包埋切片中的AT1受体、VEGF和CD34进行检测。结果:AT1受体在乳腺癌中阳性表达率为48%,在乳腺癌中有腋淋巴结转移组为61．8%,无腋淋巴结转移组为31．9%,两者差别有统计学意义(P＜0．05)。VEGF在乳腺癌中表达率为40．2%,有腋淋巴结转移组44．4%,无腋淋巴结转移组为23．5%,两者差别有统计学意义(P＜0．01)。AT1R阴性表达组的VEGF阳性表达率为11．3%(6/53),AT1R阳性表达组的VEGF阳性表达为71．4%(35/49),两者差别有统计学意义(P＜0．05); AT1R阴性表达组的MVD值为17．35±5．67,AT1R阳性表达组的MVD值为20．37±7．30,两组差别有显著性(P＜0．05)。VEGF阴性表达组的MVD表达率为17．14±5．78,VEGF阳性表达组的MVD表达为21．27±7．14,两组差别有统计学意义(P＜0．05)。结论:乳腺癌组织中AT1受体的阳性表达率为48%(49/102)AT1受体表达与患者年龄、肿瘤大小、ER、PR无相关性,而与腋淋巴结转移成正相关;乳腺癌组织中VEGF的阳性表达率为40．2%(41/102),VEGF表达与患者年龄、肿瘤大小、ER、PR无相关性,而与腋淋巴结转移成正相关;AT1受体表达与VEGF表达成正相关。在乳腺癌组织中MVD和AT1R和VEGF表达均成正相关。     

大肠癌及癌旁粘膜中CD_(44)、nm23-H_1的表达及其临床病理意义

探讨 CD44 、nm2 3- H1 的表达与大肠癌侵袭及转移的关系。应用免疫组化 SABC法检测 5 7例大肠癌组织及相应的癌旁粘膜、正常粘膜组织中 CD44 v6 、 CD44 S、 nm 2 3- H1 的表达 ,并分别比较其与大肠癌侵袭及淋巴结转移的关系。结果显示大肠癌组织 CD44 v6 的阳性率 (70 .18% )显著高于癌旁粘膜 (阳性率为 12 .0 2 % )及正常粘膜 (阳性率为 0 ) (P<0 .0 5 ) ;大肠癌组织 CD44 S和 nm2 3- H1 的阳性率 (分别为 42 .11%和 5 4.39% )显著低于癌旁粘膜 (分别为 89.47%和 91.2 3% )及正常粘膜(分别为 10 0 %和 94.74% ) (P<0 .0 5 )。CD44 v6 、nm2 3- H1 的表达与大肠癌浸润深度及淋巴结转移有相关性 (P<0 .0 5 ) ,与大肠癌分化程度无关 (P>0 .0 5 )。CD44 v6 与 nm2 3- H1 蛋白表达无明显相关性 (rs=- 0 .117,P>0 .0 5 )。结果表明 CD44 、nm2 3-H1 可作为大肠癌侵袭与淋巴结转移的重要标志     

TYK2、RASSF1A与乳腺癌临床病理参数及预后相关性

[目的]研究TYK2、RASSF1A的表达与乳腺癌临床病理参数及预后的相关性。[方法]选择乳腺癌患者240例作为研究对象,比较患者的癌症组织与癌旁组织的TYK2、RASSF1A的表达差异,分析TYK2、RASSF1A的表达与乳腺癌临床病理参数及预后的相关性。[结果]癌症组织的TYK2阳性率(54.17%)显著高于癌旁组织(14.58%),癌症组织的RASSF1A的阳性率(15.83%)显著低于对照组(45.00%)(P<0.05);患者的肿瘤直径、TNM分期、淋巴结转移、脉管转移、ER情况、PR情况以及生存情况与患者的TYK2呈现正相关,与RASSF1A呈现负相关。[结论]TYK2的异常表达与乳腺癌临床病理参数及预后呈现正相关,RASSF1A的异常表达与乳腺癌临床病理参数及预后呈现负相关,临床可将TYK2和RASSF1A表达水平作为患者预后评估的重要依据。     

七叶皂苷对P-糖蛋白功能的影响

目的:探讨七叶皂苷时P-糖蛋白功能的影响.方法:构建稳定表达P-糖蛋白的LLC-PK1细胞系,以real-time RT-PCR和Western Blotting分析P-糖蛋白基因mRNA和蛋白表达,共聚焦显微镜观察P-糖蛋白细胞定位,流式细胞术检测细胞内罗丹明123荧光强度.结果:(1)P-糖蛋白在LLC-PK1细胞中稳定高表达;(2)转染细胞中P-糖蛋白定位在细胞膜上;(3)七叶皂苷抑制P-糖蛋白功能.细胞内罗丹明123荧光强度增加123%,但其抑制效果是维拉帕米的30%.结论:七叶皂苷抑制P-糖蛋白功能,但其抑制效果弱于维拉帕米.     

P-gp、MMP-2、C-erbB-2 在乳腺癌原发灶和转移淋巴结中的表达对比研究

目的:探讨乳腺癌侵袭转移和多药耐药之间的关系,为治疗方案的个体化提供依据。方法:采用免疫组化方法检测46例乳腺浸润性导管癌患者乳腺原发灶及相应腋淋巴结转移灶中P-gp、MMP-2、c-erbB-2的表达,结合临床表现、病理学指标,分析其相关性。结果:46例原发灶P-gp阳性表达35例(76.1%),MMP-2阳性表达25例(54.3%),c-erbB-2高表达18例(39.1%);相应腋淋巴结转移灶P-gp阳性表达28例(60.9%),MMP-2阳性表达16例(34.8%),c-erbB-2高表达16例(34.8%);P-gp、MMP-2蛋白表达水平与肿块大小、淋巴结转移数目均呈正相关(P<0.05),c-erbB-2蛋白表达水平与腋窝淋巴结转移数量呈正相关,与ER、PR表达呈负相关,P-gp阳性表达与MMP-2和c-erbB-2的表达呈正相关(P<0.05)。结论:肿瘤原发灶与转移灶存在异质性,P-gp、MMP-2、c-erbB-2的表达与乳腺癌的多药耐药和侵袭转移有关,检测上述基因在原发灶与转移灶的表达,为乳腺癌选择个体化的化疗、内分泌治疗及分子靶向治疗提供了分子生物学依据。     

乳腺癌中癌胚抗原（CEA）与p53、nm23—H1蛋白表达和部分病理指标的相关性研究

利用免疫组织化学方法检测了乳腺癌CEA与p53和nm23－H1蛋白的表达,对其相关性进行了研究,同时与其它病理指标亦进行了比较。结果：82 例乳腺癌中,CEA阳性67例（82％）,与p53蛋白的表达呈显的负相关（P＜0.05）,而与nm23-H1蛋白的表达则呈显的正相关（P＜0.05）;同时,CEA的表达与肿瘤的病理分级和体积显相关（P＜0.05）,即分级越高或肿瘤越大,CEA阳性表达率越低;而与患年龄、淋巴结转移和肿瘤坏死程度无关（P＞0.05）。综合分析推测：CEA可能是乳腺癌一种高分化肿瘤标志,并与肿瘤的浸润转移潜能有一定的关系,与其它指标联合应用在判断乳腺癌预后有一定的价值。     

cyclin D1, cyclin E 在乳腺良、恶性病变中的表达及其与p16,p21waf1及Rb 蛋白的关系

为探讨cyclinD1,cyclinE在乳腺癌发生发展中的作用及其与细胞周期调控相关基因蛋白的关系,采用免疫组化检测17例非增生乳腺导管上皮、19例不同程度增生的导管上皮及59例乳腺癌中cyclinD1,cyclinE,p16,p21waf1及Rb基因蛋白的表达.结果显示1.非增生乳腺导管上皮除1例cyclinE过表达外均无cyclinD1和cyclinE的过表达.乳腺癌的cyclinD1和cyclinE的过表达率均明显高于良性乳腺组织(P<0.05).2.乳腺癌cyclinD1过表达与淋巴结转移呈正相关(P<0.05),瘤体直径大于5cm者cyclinE过表达呈增加趋势,但差异无显著性意义.3.CyclinD1和cyclinE的过表达呈正相关(P<0.05).4.从非增生乳腺导管上皮到增生直至乳腺癌,p16,p21与cyclinD1,cyclinE含量的比值逐渐递减,而p21含量高于cyclinD1的乳腺癌体积小、淋巴结转移率低(P<0.05).p21阳性率与cyclinD1过表达呈正相关(P<0.01),也随cyclinE的过表达呈上升趋势.Rb基因蛋白的强表达与cyclinD1过表达呈正相关(P<0.01).结果表明CyclinD1和cyclinE蛋白过表达频发于乳腺癌早期,它们可能与p16、p21waf1、pRb共同参与了乳腺癌的发生发展.     

DNA ploidy and vimentin expression in primary breast cancer

DNA ploidy and vimentin expression in primary breast cancer
The DNA content of 50 breast cancers of varying tumour type, grade and stage was measured using static image cytometry, and correlated with vimentin expression in the tumour cells. A tendency to increased vimentin expression and aneuploidy was observed in high grade and late stage tumours¹. A statistically significant difference was observed in DNA index and ploidy balance between grade 1 and grades 2 and 3 carcinomas ( P <0.05) and between stage I and stage II carcinomas ( P <0.05). There was a significant difference in the expression of vimentin between grades 1, 2, 3 ( P <0,001), and stages I, II and III ductal carcinomas ( P <0.05). No significant difference was observed in the proliferation index and the degree of hyperploidy ( P >0.05). Clonal heterogeneity was observed in 25% of breast carcinomas, and was associated with increased vimentin expression. These changes may be indicative of genomic alteration and tumour aggressiveness.     

外阴硬化性苔癣组织P53、PCNA表达、DNA含量及与细胞增殖的关系

探讨外阴硬化性苔癣组织中的 P5 3、PCNA表达 ,DNA含量与细胞增殖的关系。免疫组化方法测定 2 0例外阴硬化性苔癣组织和 10例正常外阴皮肤中 P5 3、 PCNA蛋白表达 ;图像分析技术检测两组基底层细胞核形态及 DNA含量。结果显示 ,外阴硬化苔癣组 P5 3阳性表达率为 40 % ,与正常皮肤比较 P<0 .0 5 ,PCNA阳性表达率为 70 % ,与正常皮肤比较 P>0 .0 5 ,阳性表达主要分布于棘层、颗粒层 ;基底细胞核显著变小和 DNA含量降低 (P<0 .0 5 )。结果表明外阴硬化性苔癣组织中存在细胞增殖异常     

Complement component 1, q subcomponent binding protein is a marker for proliferation in breast cancer

Complement component 1, q subcomponent binding protein (C1QBP), is a multi-compartmental protein with higher mRNA expression reported in breast cancer tissues. This study evaluated the association between immunohistochemical expression of the C1QBP protein in breast cancer tissue microarrays (TMAs) and clinicopathological parameters, in particular tumor size. In addition, an in vitro study was conducted to substantiate the breast cancer TMA findings. Breast cancer TMAs were constructed from pathological specimens of patients diagnosed with invasive ductal carcinoma. C1QBP protein and proliferating cell nuclear antigen (PCNA) immunohistochemical analyses were subsequently performed in the TMAs. C1QBP immunostaining was detected in 131 out of 132 samples examined. The C1QBP protein was predominantly localized in the cytoplasm of the breast cancer cells. Univariate analysis revealed that a higher C1QBP protein expression was significantly associated with older patients (P = 0.001) and increased tumor size (P = 0.002). Multivariate analysis showed that C1QBP is an independent predictor of tumor size in progesterone-positive tumors. Furthermore, C1QBP was also significantly correlated with expression of PCNA, a known marker of proliferation. Inhibition of C1QBP expression was performed by transfecting C1QBP siRNA into T47D breast cancer cells, a progesterone receptor-positive breast cancer cell line. C1QBP gene expression was analyzed by real-time RT-PCR, and protein expression by Western blot. Cell proliferation assays were also performed by commercially available assays. Down-regulation of C1QBP expression significantly decreased cell proliferation and growth in T47D cells. Taken together, our findings suggest that the C1QBP protein could be a potential proliferative marker in breast cancer.     

P53、PCNA、ki-67在大肠癌中的表达与临床意义

目的 检测P53、PCNA、ki-67在大肠癌中的表达及其与大肠癌及临床病理因素的关系,为大肠癌临床的诊疗提供一定的依据.方法 应用免疫组化法（SP法）检测53例大肠癌中P53（突变型）、PCNA、ki-67蛋白的表达.结果 P53蛋白、PCNA蛋白、Ki-67蛋白在大肠癌组织中的表达分别为67.92%、100%、86.79%,与在相对应的正常大肠粘膜组织中的表达（分别为0%、7.14%、10.71%）相比,差异有显著统计学意义（P＜0.01）.ki-67蛋白的表达和患者性别有相关性.此外,PCNA蛋白和ki-67蛋白表达呈正相关.在大肠癌中P53蛋白与PCNA蛋白、ki-67蛋白之间表达无相关性.结论 1.P53、PCNA和ki-67蛋白在大肠癌中的过表达可能与大肠癌的发生发展密切相关.2.在大肠癌组织中,PCNA、ki-67和P53之间的表达均无明显相关,提示大肠癌发生过程中肿瘤细胞的增殖与抑癌基因突变是相对独立的致病机制.3.PCNA表达与ki-67表达呈显著正相关,而PCNA表达与大肠癌患者性别无关,ki-67表达则与大肠癌患者性别有关,提示ki-67在大肠癌不同性别患者间表达差异受ki-67不同于PCNA的细胞周期影响.     

Manual versus image analysis estimation of PCNA in breast carcinoma

OBJECTIVE: To compare manual to image analysis estimation of proliferating cell nuclear antigen (PCNA) expression in paraffin sections of breast carcinomas. STUDY DESIGN: Paraffin sections of 51 breast carcinomas were stained with primary antibody to PCNA. Nuclear PCNA expression in 100 randomly selected tumor cells from marked areas was manually graded from 0 to 3. Antigen expression was also calculated by a cell analysis system (CAS-200, Becton Dickinson, Elmhurst, Illinois, U.S.A.) from marked and random microscopic fields. Obtained proliferative index (PI) from both methods was compared. RESULTS: Manually calculated PI correlated strongly with the CAS-200-calculated PI (P < .01). The highest correlation was seen between the CAS-200 PI value and manually calculated PI value using grade 2 and 3 nuclei. A particularly high correlation was noted between the number of positive nuclei and antigen staining area (P < .01) as estimated by the CAS-200. CONCLUSION: Nuclear expression of PCNA and other nuclear antigens can be accurately evaluated by an image analysis system. The speed and objectivity of such machines allow the evaluation of larger parts of tissues and provide more-representative antigen expression profiles.     

Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value

The cell proliferation markers p120, Ki-67 and proliferating cell nuclear antigen (PCNA) recognize nuclear antigens. The expression of these proteins by immunostaining methods was reported to be of value in determining the prognosis of patients with malignant diseases. In this study, we evaluated the prognostic significance of the expression of nuclear antigens p120, PCNA and Ki-67 in prostate cancer and compared the results with other prognostic factors. Imprint smear samples obtained from 70 patients immediately after radical prostatectomy for prostatic carcinoma were immunostained with monoclonal antibodies against p120, Ki-67 and PCNA. The immunostaining results were correlated with Gleason score, tumour differentiation, stage and prostatic specific antigen (PSA) levels. Our findings demonstrate that p120, Ki-67 and PCNA expression in prostatic carcinoma smears, correlated significantly with the degree of Gleason score (P < 0.001). When combining p120, Ki-67 and PCNA positivity with tumour differentiation there was a significant association among these parameters (P < 0.001). Overexpression of p120, Ki-67 and PCNA, was also associated with increased PSA serum levels (>4 ng/ml) (P < 0.001). The distribution of p120, Ki-67 and PCNA expression in prostate carcinomas was not statistically significant for Ki-67 (P = 0.69) and p120 (P = 0.22) but was significant for PCNA (P < 0.001) as far as the histological stage (T2a, T2b, T2c, T3a). P120, Ki-67 and PCNA expression had significant prognostic value for disease-free survival. Our results conclude that nuclear antigens p120, Ki-67 and PCNA appear to be additional markers in the field of prognosis of prostatic carcinoma.     

p53和c-myc异常表达与胃癌细胞多药耐药性关系的研究

应用ＳＡＢＣ免疫组织化学方法研究６７例胃标本中ｐ５３和ｃ－ｍｙｃ的表达与多药耐药性（ＭＤＲ）的关系。结果显示本组胃癌中ｐ５３阳性３２例,阳性率４７．８％;ｃ－ｍｙｃ阳性３７例,阳性率５５．２％;Ｐ－ｇｐ阳性３９例,阳性率５８．２％。ｐ５３的异常表达与ｍｄｒ－１基因表达呈显著正相关（ｒ＝０．６３,Ｐ＜０．０５）,而ｃ－ｍｙｃ和ｍｄｒ－１的表达无明显相关。提示ｐ５３异常表达可增加ｍｄｒ－１基因的表达,从而使胃癌细胞获得ＭＤＲ表型     

结直肠癌mP53 和PCNA 表达的相关性及临床意义

目的:探讨结直肠癌中突变型P53基因(mP53)和增殖细胞核抗原(PCNA)表达的相关性及临床意义。方法:应用免疫组化二步法,检测60例结直肠癌组织及20例正常肠粘膜中mP53、PCNA的表达,结合临床病理资料进行统计分析。结果:60例结直肠癌中mP53阳性表达率65.0%,PCNA阳性表达率78.3%,20例正常肠粘膜中mP53、PCNA表达均为阴性(P<0.05)。mP53和PCNA阳性表达率在低分化组、浆膜层浸润组、淋巴结转移组均较高(P均<0.05)。mP53和PCNA表达呈正相关(r=0.58,P<0.05)。结论:mP53和PCNA在结直肠癌中表达均增高,二者与结直肠癌病理学分级、浸润深度和淋巴结转移有关,可作为判断结直肠癌预后的参考指标。